Other ways to search: Events Calendar | UTHSC

Dr. Steven R. Goodman Releases New Edition of Textbook

Dr. Steven R. Goodman

Steven R. Goodman, PhD, vice chancellor for Research at the University of Tennessee Health Science Center, is known globally for his four decades of research into the structure and function of cell structures called membrane skeletons. His related research into sickle cell disease led to defining the molecular basis of the irreversibly sickle cell, and his proteomic studies led to potential biomarkers for sickle cell severity. In addition to his research legacy, Dr. Goodman has educated tens of thousands of students globally through his textbook, Medical Cell Biology. The first edition of Medical Cell Biology was published in 1993, and the tradition continues with the recent release of the fourth edition of his textbook, now called Goodman’s Medical Cell Biology.

Published by Elsevier/Academic Press, Goodman’s Medical Cell Biology, 4th Edition provides a concise focus on cell biology as it relates to human and animal disease, explaining modern cell biology principles with inclusion of multi-color illustrations and related clinical cases. The approximately 400-page text consists of 15 chapters, each with two clinical cases that provide clinical relevance to the cell biology being discussed. Used worldwide for three decades, the target audience is broad and includes professional students in medical, osteopathic, pharmacy, nursing, health professions and dentistry programs; graduate students taking cell biology; and advanced undergraduates preparing for a research and/or clinical career.

Goodman’s Medical Cell Biology, Fourth Edition

”We wrote the first edition of Medical Cell Biology, in the early 1990’s to meet our own need for a textbook for our medical students that were taking 15 lectures of cell biology within a histology course,” said Dr. Goodman. “The existing textbooks were outstanding but were well over 1000 pages long and lacked specific focus on the essential information required by future clinicians and researchers focused on human health and disease. We were able to create a 300-page textbook that resonated with lecturers and students globally. With each subsequent edition we recruited additional expert authors and updated topics and information. By the time we reached the third edition of Medical Cell Biology, it was already being translated into multiple languages. With the newly released fourth edition, we now have leading experts from around the globe as authors, five exciting new chapters, and still tell the story in a concise, roughly 400-page format. The fourth edition of Medical Cell Biology is an outstanding educational tool which I enjoyed working on with my friends from around the globe.”

Commenting on the publication, Ana Claudia Garcia, acquisitions editor at Elsevier/Academic Press, said, “Goodman’s Medical Cell Biology, 4th Edition is an important addition to the Elsevier/Academic Press textbook offerings because it comprises a tremendous wealth of knowledge in a single source not found elsewhere. This textbook is concise and helps students learn contemporary cell biology, both from the historical standpoint and from the current literature with ample illustrations and new clinical vignettes throughout the chapters. Goodman’s Medical Cell Biology is a successful student-tested textbook that has been in the market for decades.”

As editor, Dr. Goodman recruited as authors 24 outstanding experts in the various fields covered. This greatly expanded new edition features eleven new authors, five new chapters (Mitochondria and Diseases; Cell Biology of the Immune System; Stem Cells and Regenerative Medicine; Omics, Informatics, and Precision Medicine; and The Microbiome), and 28 new clinical cases. Revised and updated illustrations, all in full color, have been expanded with 150 new additions. Dr. Goodman also included a Postlude on COVID-19, which he wrote himself.

“When Goodman’s Medical Cell Biology 4th Edition was in the final stages of production, the global community was in the throes of the COVID-19 pandemic,” he said. “Many of the chapters in the book speak to the underlying cell biology of the disease. In the Postlude I was able to speak to this, but more importantly thank all of the frontline healthcare workers and researchers who continue to battle SARS-CoV-2 and give my heartfelt condolences to everyone around the globe who have lost loved ones due to COVID-19.”

Dr. Goodman tapped ten UTHSC leaders as chapter contributing authors:

  • Michael A. Whitt, PhD, professor, Department of Microbiology, Immunology and Biochemistry
  • John V. Cox, PhD, associate professor, Department of Microbiology, Immunology, and Biochemistry
  • K. Rao, PhD, AGAF, professor, Department of Physiology
  • Zhaohui Wu, MD, PhD, associate professor, Department of Radiation Oncology
  • James Kang, PhD, professor and director, Memphis Institute of Regenerative Medicine at UTHSC; Regenerative Medicine Research Center, Sichuan University (West China Hospital, China)
  • Wenjing Zhang, MD, PhD, assistant professor, Department of Genetics, Genomics and Informatics; Memphis Institute of Regenerative Medicine
  • Robert W. Williams, chair, Department of Genetics, Genomics and Informatics; UT-ORNL Governor’s Chair in Computational Genomics
  • Valeria R. Mas, PhD, professor, Department of Genetics, Genomics and Informatics; director, Transplant Research, UT/Methodist Transplant Institute
  • Ari VanderWalde, MD, MPH, MBioeth, FACP, associate professor, Department of Medicine; associate vice chancellor, Research – Clinical Trials; medical director, Office of Clinical Research
  • Karen C. Johnson, MD, MPH, professor and chair, Department of Preventive Medicine; Co-Director, TN-CTSI

For the clinical vignettes that accompany chapters 2-15, Dr. Goodman drew upon the leaders of the Clinical Trials Network of Tennessee (CTN2) and the Clinical Trials Governance Board (CTGB), and the Tennessee Clinical and Translation Science Institute (TN-CTSI). Dr. Goodman envisioned and created these three integrated statewide clinical trial networks; he also serves as president and CEO of the CTN2. Dr. Ari VanderWalde is medical director of the CTN2 and co-chair of the CTGB; Dr. Karen Johnson co-directs the TN-CTSI and is co-chair of the CTGB.

For more information on Dr. Goodman’s book, please visit: https://www.elsevier.com/books/goodmans-medical-cell-biology/goodman/978-0-12-817927-7